Search results
Laurie Hollis Glimcher (born 1951) is an American physician-scientist who was appointed president and CEO of Dana–Farber Cancer Institute in October 2016. She was elected a Member of the American Philosophical Society in 2019.
- 3; including Jake Auchincloss
Mar 15, 2017 · Laurie H. Glimcher, MD, was named President and CEO of Dana-Farber Cancer Institute in 2016. She is also Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School.
People also ask
Who is Laurie Glimcher?
Who is Dr Glimcher?
Why is Dr Glimcher a pioneer in cancer research?
Feb 27, 2024 · Glimcher is hardly the first Dana-Farber executive to recognize growing tensions between her institution and the Brigham as well as its parent company Mass General Brigham over the future of cancer care in Boston. But she is the first to confront the issue head-on.
Dec 25, 2022 · December 25, 2022. For this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Laurie Glimcher, MD, President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute (DFCI). She is also Director of the Dana-Farber/Harvard Cancer Center, Principal Investigator of Cancer ...
Laurie H. Glimcher, M.D., was named president and CEO of Dana-Farber Cancer Institute in 2016. She is also director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School.
Feb 28, 2024 · February 28, 2024. Laurie H. Glimcher, MD, president and CEO of Dana-Farber Cancer Institute, is named to STAT's 2024 STATUS List, featuring 50 influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech. Glimcher is one of eleven leaders from across the country who were ...
Jun 18, 2022 · Dr. Glimcher previously served on the Board of Directors of Bristol-Myers Squibb Pharmaceutical Corporation and the Waters Corporation. She currently serves on the Board of Directors of GlaxoSmithKline Pharmaceutical Corporation and Analog Devices, Inc.
